SeikagakuSEIKAGAKU CORPORATION4548東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
It lost about ¥2 for every ¥100 of sales at the operating level. Revenue changed -6.9% from the prior year, operating profit -149.5%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 10.7% | 0.46× | 5.0% | 1.22× | 6.1% |
| 2023 | 6.7% | 0.44× | 3.0% | 1.23× | 3.7% |
| 2024 | 6.0% | 0.46× | 2.8% | 1.29× | 3.6% |
| 2025 | 3.1% | 0.48× | 1.5% | 1.35× | 2.0% |
| 2026 | 4.0% | 0.43× | 1.7% | 1.39× | 2.4% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 34,851 | 33,456 | 36,213 | 39,374 | 36,645 |
| Cost of revenue | 14,323 | 15,432 | 19,336 | 20,221 | 20,673 |
| Gross profit | 20,528 | 18,024 | 16,877 | 19,153 | 15,972 |
| SG&A | 16,033 | 15,910 | 16,444 | 17,819 | 16,632 |
| Operating income | 4,495 | 2,114 | 433 | 1,333 | -660 |
| Pretax income | 5,395 | 3,069 | 1,691 | 1,933 | 1,510 |
| Income tax | 1,661 | 832 | -495 | 718 | 36 |
| Net income attributable to owners | 3,733 | 2,236 | 2,186 | 1,214 | 1,473 |
| Operating margin | 12.9% | 6.3% | 1.2% | 3.4% | -1.8% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥23.4B | ¥25.8B | ¥18.7B | ¥18.3B | ¥12.1B |
| Total assets | ¥75.2B | ¥75.6B | ¥81.8B | ¥83.9B | ¥86.3B |
| Net assets | ¥66.3B | ¥67.2B | ¥72.3B | ¥73.2B | ¥75.3B |
| Share capital | ¥3.84B | ¥3.84B | ¥3.84B | ¥3.84B | ¥3.84B |
| Property, plant and equipment | ¥10B | ¥11.3B | ¥15.2B | ¥18.5B | ¥22.6B |
| Intangible assets excluding goodwill | ¥2.93B | ¥3.23B | ¥3.2B | ¥3.15B | ¥2.94B |
| Goodwill | ¥2.09B | ¥2.09B | ¥2.11B | ¥1.97B | ¥1.85B |
| Investment securities | ¥12.7B | ¥13.2B | ¥18.8B | ¥19B | ¥15.7B |
| Current assets | ¥48.6B | ¥46.7B | ¥41.5B | ¥39.6B | ¥40.6B |
| Current liabilities | ¥7.53B | ¥6.7B | ¥7.2B | ¥7.9B | ¥7.59B |
| Short-term borrowings | ¥300M | ¥300M | ¥300M | ¥300M | ¥300M |
| Total liabilities | ¥8.9B | ¥8.41B | ¥9.51B | ¥10.7B | ¥11B |
| Equity attributable to owners of parent | ¥61.6B | ¥60.8B | ¥61.6B | ¥61.3B | ¥61.2B |
| Retained earnings | ¥53.3B | ¥54B | ¥54.7B | ¥54.4B | ¥54.2B |
| Treasury stock | -¥802M | -¥2.28B | -¥2.26B | -¥2.24B | -¥2.22B |
EDINET (FSA Japan)
有価証券報告書－第80期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第79期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第78期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第77期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第76期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第75期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 48 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.